Christine Ahlström
Research Subjects
Christine Ahlström has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Erik Sjögren
Department of Pharmaceutical Biosciences, Translational Drug Discovery and Development, Uppsala University, Uppsala, Sweden
2 shared publications - Hans Lennernäs
Department of Pharmaceutical Biosciences, Translational Drug Discovery and Development Uppsala University Uppsala Sweden
2 shared publications - Luna Prieto Garcia
Department of Pharmaceutical Biosciences, Translational Drug Discovery and Development, Uppsala University, Uppsala, Sweden
2 shared publications - Pär Nordell
DMPK, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
2 shared publications
Latest Publications
- Open Access
- 31 October 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (1) , 1-11
Integrated Physiologically-based Pharmacokinetic Model with a Quantitative Systems Pharmacology and Toxicology Model for Statins in Disease Population. Part 2: MIDD and MIPD Applications
The conventional strategy of prescribing the same dosage to all patients can result in suboptimal efficacy and safety. This is particularly true when considering drug-gene interactions (DGIs), drug-drug interactions (DDIs), or in individuals with compromised organ function. Precision medicine, which aims to tailor drug regimens based on individual patient characteristics, offers a promising alternative by focusing on drug disposition, efficacy, and safety. However, clinical trials face ethical and practical challenges and cannot cover all real-world patient scenarios. Thus, physiological based pharmacokinetic (PBPK) modeling offers a unique framework for enhancing model-informed drug development (MIDD) and precision dosing (MIPD). Despite this, most PBPK applications primarily assess drug pharmacokinetics without evaluating efficacy or safety outcomes. This limits the full potential of mechanistic models. In this study we used integrated PBPK, Quantitative Systems Pharmacology (QSP), and toxicology models to predict risks in scenarios like DGIs, DDIs, and varied renal impairment by simultaneously assessing drug PK, pharmacological effect, and toxicity. The findings underscore the importance of considering pharmacological effects and myotoxicity risks, which differed from changes seen in plasma exposure. This study demonstrates the value of PBPK-QSP models in guiding dose adjustments to optimize the efficacy and safety balance in target patient populations, showcasing their strength in MIDD and MIPD strategies. Graphical Abstract
- 31 October 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (1) , 1-11
Open AccessIntegrated Physiologically-based Pharmacokinetic Model with a Quantitative Systems Pharmacology and Toxicology Model for Statins in Disease Population. Part 2: MIDD and MIPD Applications
The conventional strategy of prescribing the same dosage to all patients can result in suboptimal efficacy and safety. This is particularly true when considering drug-gene interactions (DGIs), drug-drug interactions (DDIs), or in individuals with compromised organ function. Precision medicine, which aims to tailor drug regimens based on individual patient characteristics, offers a promising alternative by focusing on drug disposition, efficacy, and safety. However, clinical trials face ethical and practical challenges and cannot cover all real-world patient scenarios. Thus, physiological based pharmacokinetic (PBPK) modeling offers a unique framework for enhancing model-informed drug development (MIDD) and precision dosing (MIPD). Despite this, most PBPK applications primarily assess drug pharmacokinetics without evaluating efficacy or safety outcomes. This limits the full potential of mechanistic models. In this study we used integrated PBPK, Quantitative Systems Pharmacology (QSP), and toxicology models to predict risks in scenarios like DGIs, DDIs, and varied renal impairment by simultaneously assessing drug PK, pharmacological effect, and toxicity. The findings underscore the importance of considering pharmacological effects and myotoxicity risks, which differed from changes seen in plasma exposure. This study demonstrates the value of PBPK-QSP models in guiding dose adjustments to optimize the efficacy and safety balance in target patient populations, showcasing their strength in MIDD and MIPD strategies. Graphical Abstract
- Open Access
- 6 October 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 27 (6) , 1-13
Integrated Physiologically-Based Pharmacokinetic Model with a Quantitative Systems Pharmacology and Toxicology Model for Statins in Disease Population. Part 1: Model Development and Validation
It is important to understand the key factors affecting the pharmacokinetics (PK), pharmacological response and toxicity of a drug to ensure clinical therapeutic efficacy and safety across disease populations. Traditionally, label dose-adjustment recommendations for patient populations are based on drug plasma concentrations. However, plasma PK may not be an appropriate surrogate for response and/or toxicity for drugs like statins with intracellular targets and tissue distribution influenced by membrane transporters. This study presents the integration of a physiologically-based pharmacokinetic model with a quantitative systems pharmacology and toxicology (PBPK-QSP-TOX) model for statins in patients with normal kidney function and in different stages of chronic kidney disease (CKD). The QSP model was informed by 2753 measurements of circulating LDL concentrations in 1147 patients (NCT00654537). The TOX model was informed by a meta-analysis of creatine kinase elevation incidence per statin dose in 30 clinical studies (49,284 patients). The CKD populations accounted for disease related changes to 1) anatomy and physiology, 2) drug enzymes and transporters expression and 3) lipoprotein metabolism. This study provides a qualified PBPK-QSP-TOX model for statins that accurately describe plasma concentration–time profiles, lipid-lowering effect and myotoxicity risk over investigated dose range for patients with normal kidney function and varying degree of CKD. Graphical Abstract
- 6 October 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 27 (6) , 1-13
Open AccessIntegrated Physiologically-Based Pharmacokinetic Model with a Quantitative Systems Pharmacology and Toxicology Model for Statins in Disease Population. Part 1: Model Development and Validation
It is important to understand the key factors affecting the pharmacokinetics (PK), pharmacological response and toxicity of a drug to ensure clinical therapeutic efficacy and safety across disease populations. Traditionally, label dose-adjustment recommendations for patient populations are based on drug plasma concentrations. However, plasma PK may not be an appropriate surrogate for response and/or toxicity for drugs like statins with intracellular targets and tissue distribution influenced by membrane transporters. This study presents the integration of a physiologically-based pharmacokinetic model with a quantitative systems pharmacology and toxicology (PBPK-QSP-TOX) model for statins in patients with normal kidney function and in different stages of chronic kidney disease (CKD). The QSP model was informed by 2753 measurements of circulating LDL concentrations in 1147 patients (NCT00654537). The TOX model was informed by a meta-analysis of creatine kinase elevation incidence per statin dose in 30 clinical studies (49,284 patients). The CKD populations accounted for disease related changes to 1) anatomy and physiology, 2) drug enzymes and transporters expression and 3) lipoprotein metabolism. This study provides a qualified PBPK-QSP-TOX model for statins that accurately describe plasma concentration–time profiles, lipid-lowering effect and myotoxicity risk over investigated dose range for patients with normal kidney function and varying degree of CKD. Graphical Abstract